ArticleGlobal cardiology science & practice2013
The discovery of PCSK9 inhibitors: A tale of creativity and multifaceted translational research.
Article in Global cardiology science & practice, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis.Current cardiology reviews · 2025Pooled it
- Apolipoprotein E Mimetic Peptide-Mediated Modulation of Lipid Homeostasis.Biomolecules · 2026Review
- Genomic and Precision Medicine Approaches in Atherosclerotic Cardiovascular Disease: From Risk Prediction to Therapy-A Review.Biomedicines · 2025Review
- Genetic and biomarker approaches to uterine fibroids: toward precision medicine.Frontiers in global women's health · 2025Review
- Hypercholesterolemia: a literature review on management using tafolecimab: a novel member of PCSK9 monoclonal antibodies.Annals of medicine and surgery (2012) · 2024Review
- Is It Ever Wise to Edit Wild-Type Alleles? Engineered CRISPR Alleles Versus Millions of Years of Human Evolution.Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- How Genetics Can Improve Clinical Practice in Chronic Kidney Disease: From Bench to Bedside.Journal of personalized medicine · 2022Review
- Genomic and Phenomic Research in the 21st Century.Trends in genetics : TIG · 2019Review
- FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors.Global cardiology science & practice · 2017Article
- OSLER and ODYSSEY LONG TERM: PCSK9 inhibitors on the right track of reducing cardiovascular events.Global cardiology science & practice · 2015Article
- STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases.Global cardiology science & practice · 2015Article
- Is there an increased cardiovascular risk in metabolically healthy obese individuals? Lessons from the HUNT (Nord-Trøndelag Health) study.Global cardiology science & practice · 2014Article
- GAUSS-2, RUTHERFORD-2, LAPLACE-2, DESCARTES, and TESLA Part B: PCSK9 inhibitors gain momentum.Global cardiology science & practice · 2014Article
- PCSK 9 Inhibitors: A Short History and a New Era of Lipid-lowering Therapy.Heart views : the official journal of the Gulf Heart AssociationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.